Approved indications (U.S.): Entyvio is indicated in adults for the treatment of moderately to severely active ulcerative colitis and Crohn’s disease; the subcutaneous form is used as maintenance therapy after patients have responded to intravenous Entyvio induction infusions.

Common off-label uses:

• Chronic antibiotic-dependent or antibiotic-refractory pouchitis and Crohn’s disease of the ileal pouch, supported by phase 4 and multicenter cohort studies, though this indication is not FDA-approved in the United States.
• Other difficult inflammatory bowel conditions such as immune checkpoint inhibitor–induced colitis, typically based on case series and expert opinion rather than large randomized trials.

Efficacy expectations with subcutaneous maintenance:

• Many patients begin to notice improvement in bowel habits, bleeding, and abdominal pain within about 2–6 weeks of starting therapy, but a full assessment of benefit is usually made by around week 14.
• In clinical trials of adults who first responded to IV induction, roughly 45–50% of patients receiving Entyvio 108 mg subcutaneously every 2 weeks were in clinical remission at 1 year, with higher rates of steroid-free remission and mucosal healing than placebo.
• Compared with some systemic biologic therapies, Entyvio’s gut-selective mechanism offers similar long-term disease control for many patients with a relatively favorable safety profile, particularly regarding serious systemic infections.

Typical adult dosing (subcutaneous route): Treatment starts with Entyvio 300 mg given by intravenous infusion at weeks 0 and 2; beginning at week 6, adults who respond may switch to Entyvio 108 mg injected under the skin once every 2 weeks as ongoing maintenance for ulcerative colitis or Crohn’s disease.

How to take it: Subcutaneous Entyvio is provided as a single-dose prefilled pen or syringe injected into the thigh, abdomen (avoiding the area 2 inches around the navel), or upper arm; injections can be given with or without food at any convenient time of day, rotating injection sites and avoiding areas that are bruised, scarred, hardened, tender, or irritated.

Special administration instructions: Patients or caregivers should be trained in proper injection technique. Before use, remove the pen or syringe from the refrigerator, allow it to reach room temperature for about 30 minutes without external heat, and confirm that the solution is clear to slightly yellow and free from visible particles; do not shake, freeze, or use the device if it is dropped, damaged, or past its expiration date.

Missed dose: If a subcutaneous dose is missed or treatment is interrupted, inject the next dose as soon as possible and then continue with the usual schedule of one injection every 2 weeks; if it is unclear whether a full dose was given, contact a pharmacist or healthcare provider for instructions.

Overdose: There is no specific antidote for Entyvio; if more than the prescribed amount is given, the patient should contact their prescriber or seek medical care for monitoring and supportive management.

Common side effects: The most frequent effects (often occurring in a few percent of patients) are usually mild to moderate and may appear in the first weeks of treatment.

• Cold-like symptoms such as nasal congestion, sore throat, cough, and mild fever.
• Headache, tiredness, joint pain, back pain, and other musculoskeletal discomfort.
• Nausea, mild rash or itching.
• Injection-site reactions with the subcutaneous form (redness, itching, pain, or swelling at the injection site), which are typically mild and short-lived.

Serious or rare adverse effects needing urgent care:

• Signs of serious infection, including high fever, chills, shortness of breath, persistent cough, severe diarrhea, severe abdominal pain, or feeling very unwell.
• Severe allergic reactions such as trouble breathing, chest tightness, wheezing, swelling of the face, lips, tongue or throat, hives, or severe dizziness.
• Unexplained yellowing of the skin or eyes, dark urine, or severe right upper abdominal pain, which may indicate liver injury.
• New or worsening neurologic symptoms (such as weakness on one side, vision changes, difficulty speaking, confusion, or personality changes), which could rarely signal progressive multifocal leukoencephalopathy (PML).

Warnings and precautions: Entyvio should not be used in anyone with a known serious allergy to vedolizumab or its components. It is generally avoided in people with active, severe infections until those infections are controlled and is used cautiously in those with a history of recurrent serious infections. Liver disease may require closer monitoring, and Entyvio should be stopped if significant liver injury occurs. Data in pregnancy and breastfeeding are limited; decisions usually balance the benefit of controlling moderate-to-severe IBD against potential but uncertain risks to the fetus or infant. The safety and effectiveness of Entyvio are not established in children and adolescents under 18 years of age in the U.S.

Safety compared with similar drugs: Because Entyvio’s action is largely restricted to the gut, it tends to have a lower rate of serious systemic infections and certain immune-related complications than some broader immunosuppressive biologics, although infections and rare serious events can still occur.

Side-effect reporting and safety updates: Side effects can be reported to the U.S. Food and Drug Administration through the MedWatch program (online or by calling 1-800-FDA-1088), and patients and clinicians can consult the current Entyvio prescribing information and the FDA website for the latest safety communications.

Drug and biologic interactions: Entyvio has few direct interactions with most oral medications, but using it together with other biologic immunosuppressants such as natalizumab or tumor necrosis factor (TNF) blockers is generally avoided because of an increased risk of serious infections and PML. Combining Entyvio with other potent immunosuppressants or high-dose corticosteroids may further raise infection risk, so such regimens are used cautiously.

Vaccines, foods, alcohol, and supplements: Live vaccines are usually avoided during Entyvio treatment unless the benefits clearly outweigh the risks, while inactivated (non-live) vaccines are generally considered acceptable. There are no specific known interactions with particular foods, and moderate alcohol use does not appear to directly interfere with Entyvio, but heavy alcohol use may worsen liver or gut problems. Patients should tell their clinician about all prescription drugs, over-the-counter medicines, and herbal or dietary supplements, as overall immune suppression from combinations may influence infection risk.

Special precautions and conditions: Before starting Entyvio, clinicians typically screen for infections (such as tuberculosis) and bring vaccinations up to date. The drug is used with caution in people who have chronic or recurrent infections, significant liver disease, prior demyelinating disease, or a history suggesting increased risk of PML, and it is not recommended in those with active, severe infections until those are controlled.

Monitoring: During treatment, healthcare providers usually monitor symptoms of IBD and watch for signs of infection or neurologic change at each visit. Blood tests such as liver function tests, complete blood counts, and inflammatory markers may be checked periodically, especially in patients with liver risk factors or on additional immunosuppressants. Because improvement in inflammation can alter how the body handles some medicines, clinicians may monitor blood levels or effects of certain drugs that are sensitive CYP450 substrates when Entyvio is started or stopped.

Q: How long does it take subcutaneous Entyvio to start working?
A: Many people begin to feel some improvement in symptoms such as diarrhea, bleeding, and abdominal pain within a few weeks, but it can take up to about 3 months to see the full benefit, so doctors often reassess response around week 14.

Q: Can I give Entyvio injections to myself at home?
A: Yes, after at least two intravenous induction doses and once your healthcare provider has trained you, you or a caregiver can use the prefilled pen or syringe to inject Entyvio under the skin at home.

Q: Is the subcutaneous form as effective as the IV form?
A: In clinical studies of adults who first responded to IV Entyvio, maintenance with 108 mg subcutaneous injections every 2 weeks provided remission and mucosal healing rates similar to ongoing IV infusions, with the main difference being more mild injection-site reactions.

Q: What should I do if I miss an Entyvio injection?
A: If you miss a dose, inject it as soon as you remember and then continue with your usual schedule of one injection every 2 weeks; if you are unsure when to take the next dose, contact your healthcare provider.

Q: Do I need to stop Entyvio if I get an infection?
A: Mild infections like a common cold can often be managed without stopping treatment, but more serious infections (such as high fever, severe diarrhea, or pneumonia) may require pausing Entyvio, so you should contact your doctor promptly for advice.

Q: Is Entyvio safe during pregnancy or breastfeeding?
A: The available human data do not show a clear increase in birth defects, but experience is still limited, so decisions about using Entyvio in pregnancy or while breastfeeding are individualized and should be made in close consultation with your gastroenterologist and obstetric provider.

Storage: Store Entyvio prefilled pens or syringes in the refrigerator at 36°F to 46°F (2°C to 8°C), in the original carton to protect from light; do not freeze or shake.

They may be kept at room temperature up to 77°F (25°C) in the original carton for a single period of up to 7 days (for example, during travel); do not use the product if it has been left out longer than 7 days or exposed to direct sunlight.

Before injection: Remove the pen or syringe from the refrigerator and allow it to warm to room temperature for about 30 minutes without external heat, and use only if the liquid is clear to slightly yellow and free of visible particles.

Disposal: After use, place pens, syringes, and needles in a puncture-resistant FDA-cleared sharps container or a heavy-duty household container with a tight, puncture-resistant lid; do not discard loose sharps in household trash or recycling, and follow local rules for sharps disposal.